Pfizer to merge off-patent unit with generic drugmaker Mylan

NEW YORK – Pfizer Inc. is combining its business line of older blockbuster medicines such as Lipitor and Viagra with generic drugmaker Mylan NV, in a deal that will reshape the brand-name and off-patent pharmaceutical industries. Under the all-stock deal, a “Reverse Morris Trust” transaction, Mylan investors would get 43% of the new entity and…

Register to keep reading or subscribe today and receive unlimited access.
Register Now Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.